title: Calamitous HCV trial casts shadow over nucleoside drugs.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D002219:Carbamates; D017322:Clinical Trials, Phase II as Topic; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007674:Kidney Diseases / Q000139:chemically induced*; D009705:Nucleosides / Q000009:adverse effects*; D018579:Patient Selection; D011759:Pyrrolidines; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D009705:Nucleosides; D011759:Pyrrolidines; D012321:DNA-Directed RNA Polymerases; D014633:Valine; C549273:daclatasvir